BLFS heads into earnings with shorts retreating and EPS momentum building

Short sellers are less interested than they were a fortnight ago. SI % of free float has eased to 6.8%, down 7.5% on the week after a notable step-down around April 23. That unwinding has come despite a month-over-month increase of 2.9%, pointing to shorts building modestly through early April and then cutting positions over the past few days. The ORTEX short score has followed suit, retreating from 60.4 on April 17 to 57.2 now — still in moderate territory but clearly declining. The borrow market supports the less-crowded read: availability is wide open, cost to borrow is running at just 0.52% APR, and borrow availability has eased from a brief spike to 0.85% in mid-April back toward its recent range. FINRA's most recent settlement-date data puts days-to-cover at 10.5, but the trend in estimated shares short suggests that figure is drifting lower.

The fundamental picture underpinning the bull case is compelling, and the factor scores reinforce it. EPS surprise ranks in the 99th percentile — BLFS has a near-perfect track record of beating estimates. Forward EPS momentum is similarly strong, sitting in the 91st percentile over 30 days and the 86th over 90 days, with forward earnings growth flagged as above-average for the universe. Analysts covering the stock remain uniformly constructive: every active rating is a Buy or equivalent, with a consensus price target near $32 against a current price of $19.99 — implying roughly 62% upside. The most recent target activity (HC Wainwright in late December, maintaining a $32 Buy) is now four months old, but the direction of travel across 2025 was steadily upward. EV/EBITDA trades near 24x on the snapshot data, and the PE has compressed roughly eight points over the past month as earnings estimates have risen faster than the stock. The bear case centres on concentration risk in the CryoStor product line and the cash flow deceleration flagged through Q3 2025.

The options market has shifted modestly more defensive. The put/call ratio moved to 0.325 from a 20-day average of 0.215 — a z-score of 1.28, elevated but not extreme. For context, BLFS touched a PCR of 5.27 at its 52-week high, so the current reading is far from a stress signal. The directional shift does confirm that some participants bought protection into the earnings date.

Insider activity from the past six weeks deserves a quick read. All ten trades on record are sales — the CFO, founder/CSO, CTO, CMO, and HR Director all sold small lots in March and early April at prices between $19.12 and $19.27. The values were modest (the largest single transaction was the CFO's ~$72k sale) and the significance scores are low across the board. The 90-day net figure of +308k shares and +$6.6M USD suggests these sales are more than offset by other transactions not captured in the recent list — likely options exercises — so the selling cluster, while worth noting, does not read as a coordinated exit.

The next focal point is the May 7 Q1 print. The last two earnings events produced a day-one gain of +7.7% (February 26 Q4 report) and a day-one loss of -1.1% (March 6 event), with both followed by five-day drifts lower of roughly 8-10%. Whether the current analyst consensus, built around EPS outperformance and a recovery in biopreservation demand, gets the upgrade cycle it needs from Q1 revenue growth is the question that will frame BLFS's path from here.